TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06179615

Intervention type: OTHER
Group type: OTHER
Intervention: surface hardness test for denture teeth
Description: surface hardness test of denture teeth at insertion then after 6 months of use

Intervention type: OTHER
Group type: OTHER
Intervention: surface hardness test for denture teeth
Description: surface hardness test of denture teeth at insertion then after 6 months of use

Intervention type: OTHER
Group type: OTHER
Intervention: wear resistance of denture teeth measurement
Description: 2D, Vertical wear, 3D Volumetric wear were measured for denture teeth

Intervention type: OTHER
Group type: OTHER
Intervention: wear resistance of denture teeth measurement
Description: 2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
Study: NCT06145685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive non-surgical periodontal therapy
Description: Minimally invasive non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non-surgical periodontal therapy
Description: Conventional non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non-surgical periodontal therapy
Description: Conventional non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non-surgical periodontal therapy
Description: Conventional non-surgical periodontal therapy
Study: NCT05596630

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
Study: NCT05674045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 3mg
Description: EG017 3mg/day Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 3mg
Description: EG017 3mg/day Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG017 3mg
Description: EG017 3mg/day Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 6mg
Description: EG017 6mg/day Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 6mg
Description: EG017 6mg/day Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG017 6mg
Description: EG017 6mg/day Oral administration for 12 weeks, once daily
Study: NCT05658185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIDITRA
Description: The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:
Study: NCT06467253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1. rTMS + CS
Description: In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 2. rTMS Sham + CS
Description: In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3. tDCS + CS
Description: In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS.
Study: NCT06113861

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory secretion culture (sputum or gastric aspirate_
Description: TB culture by MODS

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory secretion culture (sputum or gastric aspirate_
Description: TB culture by MODS

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest radiograph
Description: Chest imaging test by traditional X ray

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest radiograph
Description: Chest imaging test by traditional X ray
Study: NCT06467253

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 4. tDCS Sham + CS
Description: In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS.
Study: NCT05204615

Intervention type: OTHER
Intervention: Collection of clinical, psychometric and biometric data
Description: Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
Study: NCT06469684

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health education session
Description: 1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
Study: NCT05241418

Intervention type: DIAGNOSTIC_TEST
Intervention: Atrial 3D late gadolinium enhancement
Description: We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
Study: NCT05603455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis
Description: Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05595642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W or Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W or Q4W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo Q2W
Study: NCT05106192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-Jet Injector
Description: The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-Jet Injector
Description: The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene 1% Top Gel
Description: Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrogen Mustard
Description: Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional syringe
Description: A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
Study: NCT06567743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cretostimogene Grenadenorepvec
Description: Cohort A, Arm 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cretostimogene Grenadenorepvec
Description: Cohort A, Arm 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent
Study: NCT06250751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Exercise Training (BET) intervention
Description: Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
Study: NCT04881734

Intervention type: OTHER
Intervention: Overtime pancreaticoduodenectomy
Description: Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.

Intervention type: OTHER
Intervention: Overtime pancreaticoduodenectomy
Description: Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
Study: NCT05232422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga course
Description: Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
Study: NCT06113861

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Chest imaging test by ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Chest imaging test by ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA test
Description: Blood test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA test
Description: Blood test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA test
Description: Blood test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA test
Description: Blood test for TB infection
Study: NCT06489002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Support
Description: Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
Study: NCT06329219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: water-filtered Infrared-A radiation
Description: The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
Study: NCT06060873

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06261099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control + working group
Description: Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
Study: NCT05126706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital lifestyle management
Description: Digital lifestyle management for Weight Loss Control after Thyroidectomy
Study: NCT04677621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Telehealth
Description: Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD DBS
Description: Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
Study: NCT05135130

Intervention type: DRUG
Intervention: ON101 Cream
Description: Not applicable in this retrospective study
Study: NCT06469684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education session
Description: 1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
Study: NCT05739903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (After)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (After)
Description: single dose administration (one tablet once a day)
Study: NCT04876573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine Hydrochloride 4 MG
Description: Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function.
Study: NCT04978935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care protocol
Description: Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises.
Study: NCT05150418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Oxygen 15 l/min
Study: NCT05356572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Skin Preparation Device
Description: Removal of hyperkeratotic skin with Investigational Skin Preparation Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Skin Preparation Device
Description: Removal of hyperkeratotic skin with Investigational Skin Preparation Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMDN 47102 / Electrode Skin Abrasive Pad
Description: Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UMDNS 13-230 / Biopsy punch (Dermal Curette)
Description: Removal of hyperkeratotic skin with Disposable Dermal Curette
Study: NCT06079840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness-based stress reduction app
Description: mobile application (app) for caregivers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction app
Description: mobile application (app) for caregivers
Study: NCT04765098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide 50mg/m2 daily
Study: NCT06498895

Intervention type: RADIATION
Intervention: lung ultrasound
Description: Lung ultrasound score will be done within one hour of admission,12 hours post admission then 24 hours in intensive care unit,follow up of patients will continue for 72 hours .~a complete lung ultrasound evaluation will be performed using low frequency curved probe (2MHz-5MHz) according to the lung ultrasound score . The external lung fields will be examined by longitudinal and transverse plane scans, dividing the surface of the thorax into 12 zones: 6 on the right (anterior: upper R1 and lower R2; lateral; upper R3 and lower R4; posterior: upper R5 and lower R6) and 6 on the left side (front: upper L1 and lower L2; lateral: upper L3 and lower L4; rear: upper L5 and lower L6). LUS assigns 0 points to A lines or \< 2 separate B lines plus regular sliding; 1 point with lines B ≥ 3 or spaced focal points plus regular sliding; 2 points with coalescing B lines, and 3 points to pulmonary consolidations for each zone with a score ranging from 0 (normal lungs) to 36 (worst case scenario)
Study: NCT04332666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: infusion of NaCl 0.9% without diluted peptide in it
Study: NCT05150418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Air
Description: Room air 15 l/min
Study: NCT05375019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive discipline program
Description: The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: free interaction group consisting of topics determined by the families.
Study: NCT05870371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feldenkrais Awareness Through Movement technique
Description: 10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: 10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
Study: NCT04933786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Nudging
Description: Short daily text messages with information and motivation concerning physical activity.
Study: NCT06064734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LF-rTMS
Description: H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).